Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
NCT04952168
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
26
Enrollment
OTHER
Sponsor class
Conditions
NSCLC, Stage III
Interventions
DRUG:
Almonertinib
Sponsor
Yuan Chen